March 18, 2024 Sophia Vida
Breaking News

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

New York, N.Y., March 18, 2024 – PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™ and the companies leading the charge in developing new, safe, and effective treatments for liver disease. The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), … Continue reading “PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval”